Low- versus standard-dose alteplase in patients on prior antiplatelet therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).

<h4>Background and Purpose</h4> <p>Many patients receiving thrombolysis for acute ischemic stroke (AIS) are on prior antiplatelet therapy (APT), which may increase symptomatic intracerebral hemorrhage (sICH) risk. In a pre-specified subgroup analysis, we report comparative effect...

Full description

Bibliographic Details
Main Authors:	Robinson, T, Wang, X, Arima, H, Bath, P, Billot, L, Broderick, J, Demchuk, A, Donnan, G, Kim, J, Lavados, P, Lee, T, Lindley, R, Martins, S, Olavarria, V, Pandian, J, Parsons, M, Pontes-Neto, O, Ricci, S, Sato, S, Sharma, V, Nguyen, T, Wang, J, Woodward, M, Chalmers, J, Anderson, C, ENCHANTED Investigators
Format:	Journal article
Language:	English
Published:	American Heart Association 2017

Low- versus standard-dose alteplase in patients on prior antiplatelet therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).

Similar Items